Resources

Type of publications
Regions
Diseases

5192 results found

2024 ∙ Phijffer, Ewem de Bruin, O. Ahmadizar, F. Bont, L. J. Van der Maas, N. A. T. Sturkenboom, Mcjm Wildenbeest, J. G. Bloemenkamp, K. W. M.

Respiratory syncytial virus vaccination during pregnancy for improving infant outcomes

  • Pregnant women
  • RSV (Respiratory syncytial virus)
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
High
2024 ∙ Srichawla, B. S. Fang, T. Kipkorir, V. Garcia-Dominguez, M. A.

Reversible cerebral vasoconstriction syndrome and posterior reversible encephalopathy syndrome following vaccination: analysis of the VAERS database and systematic review

  • Adults
  • Older adults
  • COVID-19
  • Measles
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2024 ∙ Vladulescu-Trandafir, A. I. Bojinca, V. C. Munteanu, C. Anghelescu, A. Popescu, C. Stoica, S. I. Aurelian, S. Balanescu, A. Baetu, C. Ciobanu, V. Onose, G.

Rheumatoid Arthritis and COVID-19 at the Intersection of Immunology and Infectious Diseases: A Related PRISMA Systematic Literature Review

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2024 ∙ Gupta, P. C. Padhi, B. K. Abu Serhan, H. Dziedzic, A. Khatib, M. N. Gaidhane, S. Zahiruddin, Q. S. Gaidhane, A. M. Kukreti, N. Rustagi, S. Satapathy, P.

Risk of Corneal Transplant Rejection Following COVID-19 Vaccination: A Systematic Review and Meta-analysis

  • All age groups
  • COVID-19
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2024 ∙ Shabani, M. Shobeiri, P. Nouri, S. Moradi, Z. Amenu, R. A. Mehrabi Nejad, M. M. Rezaei, N.

Risk of flare or relapse in patients with immune-mediated diseases following SARS-CoV-2 vaccination: a systematic review and meta-analysis

  • All age groups
  • COVID-19
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2024 ∙ Bianchi, F. P. Polignano, M. Carella, N. Rotolo, O. Curlo, M. Mastronardi, M.

Role of gastroenterologists and healthcare providers in promoting COVID-19 immunization among individuals with inflammatory bowel disease: A systematic review and meta-analysis on a global scale

  • All age groups
  • COVID-19
  • Acceptance
Methodological quality (AMSTAR 2):
Not applicable
2024 ∙ Zhuo, Y. Lu, Z. Zhang, X. Yang, Y. Han, J. Du, J. Xu, Y. Liu, Y. Fu, C.

Rubella antibody levels in the healthy Chinese population: a meta-analysis

  • Western Pacific
  • China
  • All age groups
  • Rubella
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2024 ∙ Seyedalinaghi, S. Pashaei, A. Tantuoyir, M. M. Karimi, A. Mojdeganlou, H. Nazarian, N. Vahedi, F. Afzalian, A. Shobeiri, P. Dashti, M. Ghasemzadeh, A. Mirzapour, P. Parikhani, S. N. Mehraeen, E.

Safety and Adverse Effects Related to COVID-19 Viral Vector Vaccines: A Systematic Review

  • All age groups
  • COVID-19
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2024 ∙ Ciapponi, A. Berrueta, M. Argento, F. J. Ballivian, J. Bardach, A. Brizuela, M. E. Castellana, N. Comandé, D. Gottlieb, S. Kampmann, B. Mazzoni, A. Parker, E. P. K. Sambade, J. M. Stegelmann, K. Xiong, X. Stergachis, A. Buekens, P.

Safety and Effectiveness of COVID-19 Vaccines During Pregnancy: A Living Systematic Review and Meta-analysis

  • Pregnant women
  • COVID-19
  • Safety
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2024 ∙ Beladiya, J. Kumar, A. Vasava, Y. Parmar, K. Patel, D. Patel, S. Dholakia, S. Sheth, D. Boddu, S. H. S. Patel, C.

Safety and efficacy of COVID-19 vaccines: A systematic review and meta-analysis of controlled and randomized clinical trials

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Critically low
Loading...